title: [Therapy of hormone refractory prostate cancer: new standards, new trends].
abstract: Hormone-refractory prostate cancer is diagnosed with increasing incidence and has become a growing challenge for urologists. The improved understanding of the tumor biological mechanisms of the hormone-refractory state has led to innovative therapeutic developments in the field of hormonal and cytotoxic therapies. Recently, two large randomized Phase III trials with docetaxel-based chemotherapy were able to show prolonged survival and a positive influence on pain and quality of life, establishing a new standard of care for these patients. Moreover, bisphosphonates seem to have positive influence on selected patients. In the growing field of molecular targeted therapy, first trials with compounds, such as tyrosine kinase inhibitors, anti-sense oligonucleotides, angiogenesis inhibitors and endothelin receptor antagonists, show promising results in the treatment of patients with hormone-refractory prostate cancer.
authors.affiliation: Klinik und Poliklinik für Urologie, Universitätsklinikum Münster. wulfing@uni-muenster.de
authors.forename: C
authors.initials: C
authors.lastname: Wülfing
authors.forename: S
authors.initials: S
authors.lastname: Bierer
authors.forename: M
authors.initials: M
authors.lastname: Bögemann
authors.forename: H
authors.initials: H
authors.lastname: Piechota
authors.forename: L
authors.initials: L
authors.lastname: Hertle
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D065128:Endothelin Receptor Antagonists; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D009154:Mutation; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000503:physiopathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011944:Receptors, Androgen / Q000235:genetics; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D000068878:Trastuzumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D004164:Diphosphonates; D065128:Endothelin Receptor Antagonists; D016376:Oligonucleotides, Antisense; D011944:Receptors, Androgen; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone; D011505:Protein-Tyrosine Kinases; D000068878:Trastuzumab